453 related articles for article (PubMed ID: 19369682)
21. BCR-ABL1--negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment.
Vakil E; Tefferi A
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S37-45. PubMed ID: 22035746
[TBL] [Abstract][Full Text] [Related]
22. Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment.
Hoffman R; Prchal JT; Samuelson S; Ciurea SO; Rondelli D
Biol Blood Marrow Transplant; 2007 Jan; 13(1 Suppl 1):64-72. PubMed ID: 17222772
[TBL] [Abstract][Full Text] [Related]
23. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
24. Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.
Tefferi A; Levine RL; Kantarjian H
Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):114-9. PubMed ID: 19147089
[TBL] [Abstract][Full Text] [Related]
25. Myeloproliferative neoplasms: new translational therapies.
Mascarenhas J; Hoffman R
Mt Sinai J Med; 2010; 77(6):667-83. PubMed ID: 21105128
[TBL] [Abstract][Full Text] [Related]
26. Atypical myeloproliferative disorders: diagnosis and management.
Tefferi A; Elliott MA; Pardanani A
Mayo Clin Proc; 2006 Apr; 81(4):553-63. PubMed ID: 16610578
[TBL] [Abstract][Full Text] [Related]
27. Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders.
Agarwal MB
J Assoc Physicians India; 2007 Jul; 55():507-10. PubMed ID: 17907502
[TBL] [Abstract][Full Text] [Related]
28. Molecular diagnosis of myeloproliferative neoplasms.
Patnaik MM; Tefferi A
Expert Rev Mol Diagn; 2009 Jul; 9(5):481-92. PubMed ID: 19580432
[TBL] [Abstract][Full Text] [Related]
29. JAK2 and MPL mutations in myeloproliferative neoplasms.
Koppikar P; Levine RL
Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
[TBL] [Abstract][Full Text] [Related]
30. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Tefferi A
Leukemia; 2010 Jun; 24(6):1128-38. PubMed ID: 20428194
[TBL] [Abstract][Full Text] [Related]
31. Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices.
Tefferi A
Leuk Lymphoma; 2010 Apr; 51(4):576-82. PubMed ID: 20214447
[TBL] [Abstract][Full Text] [Related]
32. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
33. Jak-2 positive myeloproliferative neoplasms.
Muxí PJ; Oliver AC
Curr Treat Options Oncol; 2014 Jun; 15(2):147-56. PubMed ID: 24627006
[TBL] [Abstract][Full Text] [Related]
34. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
[TBL] [Abstract][Full Text] [Related]
35. Mutations in the JAK2 and MPL genes and their correlation to clinical parameters in patients with chronic myeloproliferative disease.
Bojko P; Abenhardt W; Schnittger S; Haferlach T
Onkologie; 2009 Apr; 32(4):191-5. PubMed ID: 19372714
[TBL] [Abstract][Full Text] [Related]
36. The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay.
Zhang SJ; Qiu HX; Li JY; Shi JY; Xu W
Int J Lab Hematol; 2010 Aug; 32(4):381-6. PubMed ID: 20331763
[TBL] [Abstract][Full Text] [Related]
37. Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology.
Gong JZ; Cook JR; Greiner TC; Hedvat C; Hill CE; Lim MS; Longtine JA; Sabath D; Wang YL;
J Mol Diagn; 2013 Nov; 15(6):733-44. PubMed ID: 23978506
[TBL] [Abstract][Full Text] [Related]
38. Chronic myeloproliferative disorders.
Spivak JL; Barosi G; Tognoni G; Barbui T; Finazzi G; Marchioli R; Marchetti M
Hematology Am Soc Hematol Educ Program; 2003; ():200-24. PubMed ID: 14633783
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of myeloproliferative neoplasms other than chronic leukemia].
Ohyashiki JH
Nihon Rinsho; 2009 Oct; 67(10):1964-8. PubMed ID: 19860198
[TBL] [Abstract][Full Text] [Related]
40. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]